Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
6 hedge funds and large institutions have $215K invested in Hepion Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.
50% more funds holding
Funds holding: 4 → 6 (+2)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
43% less capital invested
Capital invested by funds: $380K → $215K (-$165K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$68.6K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$34.3K |
| 3 |
VF
Virtu Financial
New York
|
+$34.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$137K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Barclays
London,
United Kingdom
| $50K | +$68.6K | +2 | +200% |
|
2
HighTower Advisors
Chicago,
Illinois
| $37K | – | – | – |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $29K | -$137K | -4 | -80% |
|
|
4
Citadel Advisors
Miami,
Florida
| $27K | +$34.3K | +1 | New |
|
5
Geode Capital Management
Boston,
Massachusetts
| $17K | – | – | – |
|
|
VF
6
Virtu Financial
New York
| $16K | +$34.3K | +1 | New |
|
7
UBS Group
Zurich,
Switzerland
| $9K | – | – | – |
|
|
CS
8
Credit Suisse
Zurich,
Switzerland
| $7K | – | – | – |
|
|
TSS
9
Two Sigma Securities
New York
| $7K | – | – | – |
|
10
Northern Trust
Chicago,
Illinois
| $6K | – | – | – |
|
|
PP
11
Paloma Partners
Greenwich,
Connecticut
| $6K | – | – | – |
|
12
Morgan Stanley
New York
| $2K | – | – | – |
|
13
BlackRock
New York
| $1K | – | – | – |
|
|
LTFS
14
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
HEPA Hedge Fund Activity: Q4 2018 in Review
6 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q4 2018, worth a combined $215K — down 43% from $380K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new HEPA positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Barclays, adding an estimated $68.6K. The largest seller was Vanguard Group, cutting an estimated $137K.
- 6 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q4 2018, up from 4 in Q3 2018.
- Funds reported $215K of Hepion Pharmaceuticals stock for Q4 2018, down 43% quarter-over-quarter.
- 2 funds opened new Hepion Pharmaceuticals positions in Q4 2018 and 0 closed out, a net change of +2 holders.
- The largest Hepion Pharmaceuticals buyer in Q4 2018 was Barclays, an estimated $68.6K added.
- The largest Hepion Pharmaceuticals seller in Q4 2018 was Vanguard Group, an estimated $137K sold.
Based on aggregated 13F filings for Q4 2018.